Сочетанная терапия ингибиторами протонной помпы и клопидогрелом: фокус на сердечно-сосудистый риск
- Авторы: Кочетков А.И.1, Остроумова О.Д.1, Кравченко Е.В.2, Бондарец О.В.2, Гусева Т.Ф.2
-
Учреждения:
- ФГБОУ ВО «РНИМУ им. Н.И.Пирогова»
- ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
- Выпуск: Том 21, № 1 (2019)
- Страницы: 56-66
- Раздел: Статьи
- URL: https://journals.rcsi.science/2075-1753/article/view/96893
- DOI: https://doi.org/10.26442/20751753.2019.1.190194
- ID: 96893
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Алексей Иванович Кочетков
ФГБОУ ВО «РНИМУ им. Н.И.Пирогова»
Email: ak_info@list.ru
канд. мед. наук, науч. сотр. лаб. клинической фармакологии и фармакотерапии 16, 1-ia Leonova st., Moscow, 129226, Russian Federation
Ольга Дмитриевна Остроумова
ФГБОУ ВО «РНИМУ им. Н.И.Пирогова»
Email: ostroumova.olga@mail.ru
д-р мед. наук, проф., зав. лаб. клинической фармакологии и фармакотерапии 16, 1-ia Leonova st., Moscow, 129226, Russian Federation
Евгений Владимирович Кравченко
ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
Email: effetivo@icloud.com
студент 4-го курса лечебного фак-та 1, 20, Delegatskaia st., Moscow, 127473, Russian Federation
Ольга Валентиновна Бондарец
ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
Email: o.v.bondarets@gmail.com
канд. мед. наук, доц. каф. факультетской терапии и профболезней 1, 20, Delegatskaia st., Moscow, 127473, Russian Federation
Татьяна Федоровна Гусева
ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
Email: tguseva65@mail.ru
канд. мед. наук, доц. каф. факультетской терапии и профболезней 1, 20, Delegatskaia st., Moscow, 127473, Russian Federation
Список литературы
- Task Force Members, Montalescot G, Sechtem U et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949-3003. doi: 10.1093/eurheartj/eht296
- Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (2): 119-77. doi: 10.1093/eurheartj/ehx393
- Roffi M, Patrono C, Collet J.P et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (3): 267-315. doi: 10.1093/eurheartj/ehv320
- Valgimigli M, Bueno H, Byrne R.A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (3): 213-60. doi: 10.1093/eurheartj/ehx419
- Gutermann I.K, Niggemeier V, Zimmerli L.U et al. Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines. Medicine (Baltimore). 2015; 94 (1): e377. doi: 10.1097/MD.0000000000000377
- Neumann F.J, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40 (2): 87-165. doi: 10.1093/eurheartj/ehy394
- Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50 (5): e1-e88.
- Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15 (5): 625-51. doi: 10.1093/europace/eut083
- Levine G.N, Bates E.R, Bittl J.A et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68 (10): 1082-115. doi: 10.1016/j.jacc.2016.03.513
- Hu W, Tong J, Kuang X et al. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis. Medicine (Baltimore) 2018; 97 (3): e9638. doi: 10.1097/MD.0000000000009638
- Serbin M.A, Guzauskas G.F, Veenstra D.L. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. J Manag Care Spec Pharm 2016; 22 (8): 939-47. doi: 10.18553/jmcp.2016.22.8.939
- Zairis M.N, Tsiaousis G.Z, Patsourakos N.G et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol 2010; 26 (2): e54-7.
- Evanchan J, Donnally M.R, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol 2010; 33 (3): 168-71. doi: 10.1002/clc.20721
- Harjai K.J, Shenoy C, Orshaw P et al. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. Circ Cardiovasc Interv 2011; 4 (2): 162-70. doi: 10.1161/CIRCINTERVENTIONS.110.958884
- Aihara H, Sato A, Takeyasu N et al. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry. Catheter Cardiovasc Interv 2012; 80 (4): 556-63. doi: 10.1002/ccd.23327
- Bundhun P.K, Teeluck A.R, Bhurtu A, Huang W. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty: a systematic review and meta-analysis of recently published studies (2012-2016). BMC Cardiovasc Disord 2017; 17 (1): 3. doi: 10.1186/s12872-016-0453-6
- Douglas I.J, Evans S.J, Hingorani A.D et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 2012; 345: e4388. doi: 10.1136/bmj.e4388
- Bhurke S.M, Martin B.C, Li C et al. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 2012; 32 (9): 809-18. doi: 10.1002/j.1875-9114.2012.01112.x
- Dunn S.P, Steinhubl S.R, Bauer D et al. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2013; 2 (1): e004564. doi: 10.1161/JAHA.112.004564
- Goodman S.G, Clare R, Pieper K.S et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012; 125 (8): 978-86. doi: 10.1161/CIRCULATIONAHA.111.032912
- Hsieh C.F, Huang W.F, Chiang Y.T et al. Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study. PLoS One 2015; 10 (8): e0135915. doi: 10.1371/journal.pone.0135915
- Chitose T, Hokimoto S, Oshima S et al. Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 2012; 76 (1): 71-8.
- Macaione F, Montaina C, Evola S et al. Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol 2012; 2012: 692761. doi: 10.5402/2012/692761
- Burkard T, Kaiser C.A, Brunner-La Rocca H et al. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med 2012; 271 (3): 257-63. doi: 10.1111/j.1365-2796.2011.02423.x.
- Gargiulo G, Costa F, Ariotti S et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. Am Heart J 2016; 174: 95-102. doi: 10.1016/j.ahj.2016.01.015
- Steinhubl S.R, Berger P.B, Mann J.T 3rd et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19): 2411-20.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348 (9038): 1329-39.
- Huang B, Huang Y, Li Y et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res 2012; 43 (3): 212-24. doi: 10.1016/j.arcmed.2012.04.004
- Focks J.J, Brouwer M.A, van Oijen M.G et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart 2013; 99 (8): 520-7. doi: 10.1136/heartjnl-2012-302371
- Demcsák A, Lantos T, Bálint E.R et al. PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis. Front Physiol 2018; 9: 1550. doi: 10.3389/fphys.2018.01550
- Melloni C, Washam J.B, Jones W.S et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes 2015; 8 (1): 47-55. doi: 10.1161/CIRCOUTCOMES.114.001177
- Ng F.H, Tunggal P, Chu W.M et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 2012; 107 (3): 389-96. doi: 10.1038/ajg.2011.385
- Yano H, Tsukahara K, Morita S et al. Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. Circ J 2012; 76 (11): 2673-80.
- Hsu P.I, Lai K.H, Liu C.P. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011; 140 (3): 791-8. doi: 10.1053/j.gastro.2010.11.056
- Ren Y.H, Zhao M, Chen Y.D et al. Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Chin Med J (Engl) 2011; 124 (6): 856-61.
- Bhatt D.L, Cryer B.L, Contant C.F et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363 (20): 1909-17. doi: 10.1056/NEJMoa1007964
- Cai J, Wu Q, Fan L et al. Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2010; 26 (3): 266-9.
- Weisz G, Smilowitz N.R, Kirtane A.J et al. Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study. Circ Cardiovasc Interv 2015; 8 (10). pii: e001952. doi: 10.1161/CIRCINTERVENTIONS.114.001952
- O'Donoghue M.L, Braunwald E, Antman E.M et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374 (9694): 989-97. doi: 10.1016/S0140-6736(09)61525-7
- Tentzeris I, Jarai R, Farhan S et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 2010; 104 (6): 1211-8. doi: 10.1160/TH10-04-0218
- Sarafoff N, Sibbing D, Sonntag U et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost 2010; 104 (3): 626-32. doi: 10.1160/TH09-11-0800
- Chandrasekhar J, Bansilal S, Baber U et al. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv 2017; 89 (7): E217-E225. doi: 10.1002/ccd.26716
- Комаров А.Л., Шахматова О.О., Мурасеева В. и др. Прием ингибиторов протонной помпы и прогноз пациентов после плановых чрескожных коронарных вмешательств. Терапевтический архив. 2018; 9: 92-100.